Description

PRL 2915 is a potent human somatostatin subtype 2 receptor (hsst2) antagonist with a Ki of 12 nM[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Metabolism-protein/nucleotide metabolism–C59H71ClN12O8S2—-[1]Hocart SJ, et al. Highly potent cyclic disulfide antagonists of somatostatin. J Med Chem. 1999 Jun 3;42(11):1863-71.|[2]Rossowski WJ, et al. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur J Pharmacol. 2002 Mar 8;438(3):159-70.–209006-18-8–1175.85–99.57–O=C([C@@H](NC([C@@H](CSSC[C@H](NC([C@@H](NC([C@@H](NC1=O)CCCCN)=O)C(C)(C)C)=O)C(N[C@H](C(N)=O)CC2=CC3=C(C=CC=C3)C=C2)=O)NC([C@@H](N)CC4=CC=C(C=C4)Cl)=O)=O)CC5=CN=CC=C5)N[C@@H]1CC6=CNC7=CC=CC=C67–Endocrinology–DMSO : 100 mg/mL (ultrasonic)–Somatostatin Receptor;Urotensin Receptor–SSTR1;SSTR2;SSTR3;SSTR4;SSTR5–GPCR/G Protein;Neuronal Signaling–Peptides